A5083232282- SARS-CoV-2 and COVID-19 Research
- SARS-CoV-2 detection and testing
- RNA Interference and Gene Delivery
- Cancer Immunotherapy and Biomarkers
- COVID-19 Clinical Research Studies
- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
- Immunotherapy and Immune Responses
Federal Medical-Biological Agency
2022-2025
Sechenov University
2023
IFC Research (United Kingdom)
2023
Severe acute respiratory syndrome corona virus (SARS-CoV-2) infection frequently causes severe and prolonged disease but only few specific treatments are available. We aimed to investigate safety efficacy of a SARS-CoV-2-specific siRNA-peptide dendrimer formulation MIR 19® (siR-7-EM/KK-46) targeting conserved sequence in known SARS-CoV-2 variants for treatment COVID-19.We conducted an open-label, randomized, controlled multicenter phase II trial (NCT05184127) evaluating inhaled...
ABSTRACT Background COVID‐19 continues to be a major global health challenge. Inhaled siRNA‐based MIR 19 has been shown reduce the time clinical improvement in patients hospitalized with moderate COVID‐19. Methods We conducted an open‐label, randomized, controlled multicenter phase 2b‐3 trial (NCT05783206) evaluating safety and efficacy of inhaled siR‐7‐EM/KK‐46 (MIR 19) (5.55 mg/day) comparison standard care (control group) outpatients mild ( N = 492 for each group). The primary endpoint...
Результаты I и II фазы клинических исследований препарата МИР 19 ® 1 Федеральное государственное бюджетное учреждение «Государственный научный центр «Институт иммунологии» Федерального медико-биологического агентства, 115522, г.Москва, Российская Федерация 2 автономное образовательное высшего образования «Российский национальный исследовательский медицинский университет имени Н.И.Пирогова» Министерства здравоохранения Российской Федерации, 117997, 3 научное «Научно-исследовательский институт...
BACKGROUND Severe acute respiratory syndrome corona virus (SARS-CoV-2) infection frequently causes severe and prolonged disease but only few specific treatments are available. We aimed to investigate safety efficacy of a SARS-CoV-2-specific siRNA-peptide dendrimer formulation (MIR 19 ®) targeting conserved sequence in known SARS-CoV-2 variants for treatment COVID-19. METHODS conducted an open-label, randomized controlled multicenter phase II trial (NCT05184127) evaluating inhaled MIR ®...